Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABOS Acumen Pharmaceuticals	$1.39 +9.4%	$1.31	$0.86 ▼ $3.36	$84.14M	0.14	333,899 shs	224,323 shs
CARA Cara Therapeutics		$15.19	$8.13 ▼ $19.08	$24.33M	0.41	22,224 shs	237,144 shs
IVVD Invivyd	$0.79 -0.3%	$0.77	$0.35 ▼ $2.74	$94.89M	0.51	7.05 million shs	233,444 shs
PLRX Pliant Therapeutics	$1.58 -1.6%	$1.44	$1.10 ▼ $16.10	$96.69M	1.42	1.76 million shs	2.68 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABOS Acumen Pharmaceuticals	+0.79%	-9.29%	-14.77%	+25.74%	-54.15%
CARA Cara Therapeutics	0.00%	0.00%	0.00%	0.00%	+31.16%
IVVD Invivyd	+1.63%	+10.60%	+8.63%	+12.64%	-25.19%
PLRX Pliant Therapeutics	-4.76%	-5.33%	+10.34%	+16.79%	-86.96%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABOS Acumen Pharmaceuticals	3.2347 of 5 stars	3.5	5.0	0.0	2.3	1.7	0.6
CARA Cara Therapeutics	0.2137 of 5 stars	0.0	0.0	4.2	0.0	0.8	0.0
IVVD Invivyd	3.8895 of 5 stars	3.6	5.0	0.0	3.1	3.3	0.6
PLRX Pliant Therapeutics	3.7889 of 5 stars	3.0	2.0	4.7	1.7	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABOS Acumen Pharmaceuticals	3.00	Buy	$6.33	355.96% Upside
CARA Cara Therapeutics	0.00	N/A	N/A	N/A
IVVD Invivyd	3.25	Buy	$5.85	639.57% Upside
PLRX Pliant Therapeutics	2.08	Hold	$8.19	419.84% Upside

Current Analyst Ratings Breakdown

Latest CARA, PLRX, ABOS, and IVVD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/10/2025	PLRX Pliant Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
8/8/2025	PLRX Pliant Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$17.00 ➝ $4.00
6/26/2025	IVVD Invivyd	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/26/2025	IVVD Invivyd	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
6/17/2025	ABOS Acumen Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$4.00
5/28/2025	IVVD Invivyd	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $5.00
5/16/2025	IVVD Invivyd	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABOS Acumen Pharmaceuticals	N/A	N/A	N/A	N/A	$3.03 per share	N/A
CARA Cara Therapeutics	$7.14M	0.00	N/A	N/A	$12.58 per share	0.00
IVVD Invivyd	$36.69M	2.59	N/A	N/A	$0.56 per share	1.41
PLRX Pliant Therapeutics	N/A	N/A	N/A	N/A	$3.59 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABOS Acumen Pharmaceuticals	-$102.33M	-$2.28	N/A	N/A	N/A	N/A	-73.93%	-57.71%	N/A
CARA Cara Therapeutics	-$118.51M	-$21.01	N/A	N/A	N/A	-1,099.76%	-367.97%	-107.43%	N/A
IVVD Invivyd	-$169.93M	-$1.20	N/A	7.19	N/A	-389.01%	-165.24%	-99.71%	N/A
PLRX Pliant Therapeutics	-$210.30M	-$3.40	N/A	N/A	N/A	N/A	-73.45%	-55.66%	N/A

Latest CARA, PLRX, ABOS, and IVVD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	ABOS Acumen Pharmaceuticals	-$0.54	-$0.68	-$0.14	-$0.68	N/A	N/A
8/7/2025	Q2 2025	PLRX Pliant Therapeutics	-$0.62	-$0.71	-$0.09	-$0.71	N/A	N/A
5/15/2025	Q1 2025	IVVD Invivyd	-$0.04	-$0.14	-$0.10	-$0.14	$34.45 million	$11.30 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABOS Acumen Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CARA Cara Therapeutics	N/A	N/A	N/A	N/A	N/A
IVVD Invivyd	N/A	N/A	N/A	N/A	N/A
PLRX Pliant Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABOS Acumen Pharmaceuticals	0.19	8.02	8.02
CARA Cara Therapeutics	N/A	4.77	4.71
IVVD Invivyd	N/A	1.53	1.53
PLRX Pliant Therapeutics	0.14	12.99	12.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABOS Acumen Pharmaceuticals	71.01%
CARA Cara Therapeutics	44.66%
IVVD Invivyd	70.36%
PLRX Pliant Therapeutics	97.30%

Insider Ownership

Company	Insider Ownership
ABOS Acumen Pharmaceuticals	9.30%
CARA Cara Therapeutics	3.10%
IVVD Invivyd	25.40%
PLRX Pliant Therapeutics	8.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABOS Acumen Pharmaceuticals	20	60.57 million	54.94 million	Optionable
CARA Cara Therapeutics	80	4.57 million	4.43 million	Optionable
IVVD Invivyd	100	119.96 million	89.49 million	Optionable
PLRX Pliant Therapeutics	90	61.39 million	56.48 million	Optionable

CARA, PLRX, ABOS, and IVVD Headlines

Recent News About These Companies

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Average Rating of "Hold" by Brokerages

August 13 at 2:51 AM | americanbankingnews.com

Pliant Therapeutics price target raised to $1.70 from $1.50 at Citi

August 11 at 10:40 AM | msn.com

Piper Sandler Issues Pessimistic Forecast for Pliant Therapeutics (NASDAQ:PLRX) Stock Price

August 10, 2025 | americanbankingnews.com

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Consensus Recommendation of "Hold" from Brokerages

August 9, 2025 | marketbeat.com

Pliant Therapeutics (NASDAQ:PLRX) Price Target Lowered to $4.00 at Piper Sandler

August 9, 2025 | marketbeat.com

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

August 7, 2025 | globenewswire.com

XTX Topco Ltd Makes New $630,000 Investment in Pliant Therapeutics, Inc. (NASDAQ:PLRX)

August 6, 2025 | marketbeat.com

Pliant Therapeutics (PLRX) to Release Earnings on Wednesday

August 5, 2025 | americanbankingnews.com

Pliant Therapeutics (PLRX) Expected to Announce Earnings on Wednesday

July 30, 2025 | marketbeat.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sangamo Biosciences (SGMO), Pliant Therapeutics (PLRX) and Stevanato Group (STVN)

July 24, 2025 | theglobeandmail.com

Pliant Therapeutics Provides Update on BEACON-IPF

June 27, 2025 | globenewswire.com

Alnylam, Pliant among stocks yet to face Q2 catalysts: Wells Fargo

June 7, 2025 | msn.com

Pliant Therapeutics presents new fibrosis treatment data

May 23, 2025 | investing.com

Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference

May 21, 2025 | finance.yahoo.com

Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference

May 21, 2025 | globenewswire.com

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 8, 2025 | globenewswire.com

Pliant Therapeutics announces workforce reduction

May 3, 2025 | uk.investing.com

Pliant Therapeutics Announces Workforce Reduction and Cost Saving Initiatives to Support Late-Stage Clinical Trials

May 3, 2025 | nasdaq.com

Bay Area biotech company Pliant Therapeutics slashes staff after losing $655 million in value

May 2, 2025 | msn.com

Pliant Axes 45% of Workforce To Save Cash, Support Late-Stage Clinical Trials

May 2, 2025 | biospace.comB

Pliant Therapeutics cuts workforce by 45% after bexotegrast trial safety woes

May 2, 2025 | fiercebiotech.comF

New MarketBeat Followers Over Time

Media Sentiment Over Time

CARA, PLRX, ABOS, and IVVD Company Descriptions

Acumen Pharmaceuticals NASDAQ:ABOS

$1.39 +0.12 (+9.37%)

Closing price 03:59 PM Eastern

Extended Trading

$1.40 +0.01 (+0.43%)

As of 04:10 PM Eastern

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Cara Therapeutics NASDAQ:CARA

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Invivyd NASDAQ:IVVD

$0.79 0.00 (-0.25%)

Closing price 03:59 PM Eastern

Extended Trading

$0.78 -0.01 (-1.26%)

As of 04:13 PM Eastern

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

Pliant Therapeutics NASDAQ:PLRX

$1.58 -0.03 (-1.56%)

Closing price 03:59 PM Eastern

Extended Trading

$1.58 0.00 (0.00%)

As of 04:10 PM Eastern

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time